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Significance Statement
The current research identified two lncRNAs, HNF1α-AS1 and HNF4α-AS1, which were able to affect susceptibility of AILI in HepaRG cells, possibly through regulating the expression of APAP-metabolizing P450 enzymes. This discovery added new factors, lncRNAs, which can be used to predict P450-mediated drug metabolism and druginduced toxicity.
Introduction
Acetaminophen (APAP), or N-acetyl-p-aminophenol, is one of the most commonly used over-the-counter drugs for its antipyretic or analgesic effects in the treatment of fever or management of pain (Bunchorntavakul and Reddy, 2013) . APAP is a safe drug if used properly. The maximal dose of 4,000 mg per day suggested by the US Food and Drug Administration is considered to be safe and generally does not cause liver toxicity (Yoon et al., 2016) . However, APAP overdose can result in severe APAP-induced liver injury (AILI). Previous reports have indicated that AILI is one of the most common causes of liver damage and acute liver failure in the United States (Ostapowicz et al., 2002; Herndon and Dankenbring, 2014) . Furthermore, APAP-related deaths, mostly caused by liver failure, are much more than those liver failure fatalities caused by all other prescription drugs combined (Lee, 2017) . Considerable efforts have been made to understand the mechanisms responsible for AILI in different in vivo and in vitro models. N-acetyl-pbenzoquinone imine (NAPQI), the active metabolite of APAP by cytochrome P450s (CYPs), has been proven to cause cellular stress and damage through several pathways, including induction of oxidative stress (Xie et al., 2014) . In this case, the metabolism of APAP by CYPs to NAPQI has been regarded as a critical step in the development of AILI (Laine et al., 2009) .
CYPs are a group of heme-containing enzymes, which catalyze the metabolism of a broad range of endogenous compounds, environmental chemicals, and drugs (Gonzalez, 1988) . The expression and function of CYPs are critical factors in the maintenance of human health and therapeutic efficacy of drugs. However, great inter-individual variability has been observed in CYP expression and functions as well as CYP-mediated drug This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on February 6, 2020 as DOI: 10.1124/mol.119.118778 at ASPET Journals on February 14, 2020 molpharm.aspetjournals.org Downloaded from metabolism (Tracy et al., 2016) . Several CYP subfamily members, including CYP1A2, 2E1, and 3A4, have been proven to mediate biotransformation of APAP to NAPQI, which are important mediators for predicting AILI (Tonge et al., 1998) .
Multiple regulatory factors and mechanisms are involved in the regulation of CYP expression. Genetic and epigenetic regulations are among the most widely studied factors contributing to differential metabolism of drugs among individuals (Gomez and Ingelman-Sundberg, 2009; Zanger and Schwab, 2013; Tang and Chen, 2015) .
Furthermore, recent studies also showed that several factors known to affect APAPmetabolizing CYP enzymes are able to alter APAP metabolism and AILI outcome (Court et al., 2017) . However, these studies mainly focus on the roles of genetic polymorphisms in the CYP genes, which can only account for a small portion of the inter-individual differences in expression of CYPs and ability to metabolize drugs (Pinto and Dolan, 2011) . More factors and mechanisms are needed to be discovered to fully understand this process.
LncRNAs are RNA transcripts from non-coding genes with a length of more than 200 nucleotides (Cabili et al., 2011) . Recent studies have shown that the overwhelmingly abundant lncRNAs, comparing to coding RNAs, in human and other species have important functions in multiple physiological processes, including development, cell differentiation, and immune response (Fatica and Bozzoni, 2014; Perry and Ulitsky, 2016; Agirre et al., 2019; Fernandes et al., 2019) . Increasing evidence shows that lncRNAs are also important for the metabolism processes (Kornfeld and Bruning, 2014; Li et al., 2019) .
However, how lncRNAs regulate CYP-mediated drug metabolism and the toxicological consequences on CYP-generated metabolites are still not fully understood.
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Neighborhood antisense lncRNAs are a common phenomenon in multiple living organisms, including human (Villegas and Zaphiropoulos, 2015) . Several examples have suggested that the existence of neighborhood antisense lncRNAs is critical for the function of their neighborhood coding genes (Zhou et al., 2015; Khyzha et al., 2019) .
LncRNAs hepatocyte nuclear factor 1α (HNF1α) antisense RNA 1 (HNF1α-AS1) and HNF4α antisense RNA 1 (HNF4α-AS1) are neighborhood antisense lncRNAs of the transcription factors HNF1α and HNF4α, respectively. These two lncRNAs have been reported to regulate mRNA levels of several CYPs (including CYP1A2, 2E1, and 3A4) in opposing manners in in vitro models Wang et al., 2019a) . Based on this observation, we hypothesize that the lncRNAs HNF1α-AS1 and HNF4α-AS1 have opposite effects modulating AILI via alterations in APAP metabolism by CYPs. To test the hypothesis, transfection of small hairpin RNA (shRNA) containing vectors were used to knock down HNF1α-AS1 and HNF4α-AS1 in HepaRG cells, a reliable in vitro model to study hepatotoxicity caused by APAP (McGill et al., 2011) . Cytotoxicity generated by APAP was determined by several different toxicity assays, including 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, lactate dehydrogenase (LDH) release, and dihydrorhodamine 123 (DHR123) staining assays.
Alterations in mRNA and protein levels of APAP-metabolizing phase I and II enzymes were determined by quantitative real-time PCR (RT-PCR) and Western blots,
respectively.
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shRNA Transfection. To generate lncRNA loss-of-function HepaRG models, plasmid vector-containing shRNAs with different targets were designed and purchased from GeneCopoeia (Rockville, MD, USA). The transfection processes were performed according to a previous study with minor modifications (Brauze et al., 2017) . Briefly, HepaRG cells are seeded in collagen I coated 6-well plates with a concentration of ~50,000 cells/well. Plasmid transfection was performed when the cells reached to ~90% confluence. Liposomes were prepared by mixing 1 μg shRNA-containing vector in 50 µL
Opti-MEM medium with 5 µl Lipofectamine™ stem transfection reagent in 50 µl Opti-MEM.
After incubation for 20 minutes at room temperature, the DNA-lipid complexes were added to HepaRG cells. A puromycin selection (3 μg/ml) was performed after the transfection to select transfected cells. Cells were then cultured to a fully differentiated status.
Drug Treatment. Differentiated HepaRG cells (transfected with shNC, shHNF1α-AS1, or shHNF4α-AS1) were seeded into collagen-I coated 96-well plates with a density of 20,000 cells/well. Cells were incubated overnight for attachment before treatment. Cells were then treated with 0, 10, 30, or 100 mM of APAP in PBS for 24 h.
MTT Assay. Cell viability was measured by the MTT assay according to the manufacturer's protocol. Briefly, after APAP treatment, 20 µL of MTT solution (4 mg/ml) was added to each well and the plates were incubated for 3.5 h in a 37°C incubator. After incubation, the remaining solution was removed carefully from the plates and 100 µL of dimethyl sulfoxide (DMSO) was added to each well to dissolve formed crystal. The plates This article has not been copyedited and formatted. The final version may differ from this version. shHNF1α-AS1, or shHNF4α-AS1) were seeded into collagen-I coated chamber slides with a density of 100,000 cells/well and incubated overnight for attachment. Cells were then treated with 10 mM of APAP in a 500-µL culturing medium for 24 h. After the treatment, the medium was removed and cells were rinsed once with PBS. Diluted DHR123 solution (5 µM) was then added to each well and plates were incubated for 45 min with protection from light. After incubation, the DHR123 solution was replaced with This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Impact on APAP-induced Cytotoxicity by Knockdown of HNF1α-AS1 and
HNF4α-AS1. To study the roles of the lncRNAs, HNF1α-AS1 and HNF4α-AS1, in affecting the cytotoxicity of APAP, HepaRG cells were stably transfected with shRNAs targeting these two lncRNAs as well as a negative control. Several assays measuring APAP cytotoxicity, including MTT, LDH release, and HDR123 staining assays were performed. Knockdown of HNF1α-AS1 and HNF4α-AS1 by shRNA transfection in HepaRG cells yielded a decrease in their RNA levels to 0.41-fold (95% confidence interval CI = 0.24 to 0.58, ***p<0.001) and 0.46-fold (CI = 0.23 to 0.71, **p<0.01) comparing to their control groups (cells transfected with shNC), respectively, which is indicative of successful knockdown ( Fig. 1A and 1B ). Cells with stable lncRNA knockdown were then treated with different concentrations of APAP for the assessment of cytotoxicity.
The MTT assay was performed to test cell viability after APAP challenge. Cells were treated with different concentrations of APAP (0, 10, 30, or 100 mM) for 24 h. Cell viability was normalized to the control group (cells transfected with shNC receiving no APAP treatment). As shown in Fig. 2A , knockdown of HNF1α-AS1 and HNF4α-AS1 did not alter cell viability in non-APAP challenged cells. However, when treated with APAP at concentrations of 10 or 30 mM, cells with lncRNAs knockdown showed a differential susceptibility to APAP toxicity. Specifically, knockdown of HNF1α-AS1 led to increases in cell viability when treated with APAP at concentrations of 10 or 30 mM, while the opposite was observed in HNF4α-AS1 knockdown cells, where the cell viability was lower at the same APAP concentrations ( Fig. 2A) . These results indicate that these lncRNAs play opposing roles in the susceptibility to APAP-induced cytotoxicity. At 100 mM APAP, which This article has not been copyedited and formatted. The final version may differ from this version. is a highly toxic concentration, no differences in cytotoxicity were observed and cell viability was low among all three groups of HepaRG cells.
The LDH release assay was used for detecting extent of cell damage. Aside from cell death, damage of living cells was another parameter to assess drug-induced cytotoxicity.
As expected, Fig. 2B shows no increases in LDH release after knockdown of HNF1α-AS1
and HNF4α Overproduction and accumulation of reactive oxygen species (ROS) and induction of oxidative stress is one of the main features for AILI. Fig. 3 shows the analysis of ROS production by DHR123 staining. Under normal conditions, no fluorescence was detected in any of the groups of cells (data not shown). However, with APAP treatment, differences in fluorescent intensity were observed. Positive stained cells, indicative of ROS accumulation, were observed in all three groups of cells exposed to 10 mM APAP (Fig.   3A ). Quantification results (Fig. 3B ) showed that cells with HNF4α-AS1 knockdown had This observation indicates that the production of ROS co-localizes to cells where CYPmediated bioactivation of APAP occurs. The cells with HNF4α-AS1 knockdown showed an observable brighter green fluorescence compared to other groups, indicating higher levels of ROS, which is consistent with higher toxicity in those cells. By contrast, fewer positive stained cells and dimmed green fluorescence were detected in HNF1α-AS1 knockdown cells, indicating lower levels of ROS, which is also in agreement with the higher tolerance of these cells to APAP.
The results from the cytotoxicity assays performed here provided strong evidence that knockdown of lncRNA HNF1α-AS1 or HNF4α-AS1 altered cell susceptibility to APAP cytotoxicity. The absence of HNF4α-AS1 increased susceptibility to APAP-induced cytotoxicity, while deletion of HNF1α-AS1 afforded tolerance to APAP cytotoxicity.
Impact on Metabolic Pathways of APAP by Knockdown of HNF4α-AS1 and
HNF1α-AS1. To determine how knockdown of HNF1α-AS1 and HNF4α-AS1 affects APAP-induced cytotoxicity, the enzymes involved in the metabolic pathways of APAP were examined. As shown in Fig. 4 , APAP is metabolized by several phase I and II enzymes, whose combined functions ultimately determine cytotoxicity outcome. NAPQI, the toxic metabolite, is produced by CYP-mediated bioactivation of APAP. The major CYPs involved in this process are CYP1A2, 2E1, and 3A4. Several phase II enzymes, including SULT1A1, UGT1A1, and 1A9, are also able to biotransform APAP, forming nontoxic APAP-conjugates. Furthermore, NAPQI can be detoxified by reacting with cellular glutathione, mediated by GSTP1 and GSTT1. The mRNA levels of these genes were Collectively, these data indicate that lncRNAs HNF1α-AS1 and HNF4α-AS1 are involved in the regulation of functional activity of biotransformation pathways for APAP, ultimately impacting APAP-induced cytotoxicity.
HNF4α-AS1 knockdown produced no changes in mRNA levels of selected phase II enzymes, including SULT1A1, UGT1A1, and 1A9 (Fig. 6A ). The mRNA levels of SULT1A1 and UGT1A9 was decreased by knockdown of HNF1α-AS1 to 0.64-fold (CI = 0.48 to 0.80, *p<0.05) and 0.72-fold (CI = 0.59 to 0.85, *p<0.05) comparing to the control group, respectively, while no changes in the mRNA level of UGT1A1 was found. For GSTs, the mRNA levels of GSTT1 were comparable among all three groups of cells. Even though the decreases in mRNA levels of GSTP1 by knockdown of both HNF1α-AS1 and HNF4α-AS1 were detected (Fig. 6B) , considering the expression level of GSTP1 in believed to cause major changes in APAP metabolism and cytotoxicity.
Taken together, these results indicate that the changes in mRNA and protein levels of CYP enzymes by knockdown of HNF1α-AS1 and HNF4α-AS1 are the most likely mechanisms for the differential susceptibility to APAP-induced cytotoxicity in HepaRG cells.
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Discussion
Regulation of transcription factors including HNF1α and HNF4α, either by gene edition techniques or endogenous miRNAs, has been reported to affect cellular response to APAP-induced cytotoxicity (Martovetsky et al., 2013; Li et al., 2014; Yu et al., 2018) . The current study also proves that the neighborhood antisense lncRNAs HNF1α-AS1 and HNF4α-AS1 also affect APAP-induced cytotoxicity independently. The manipulation of expression of HNF1α-AS1 and HNF4α-AS1 alone is unable to affect expression of HNF1 and HNF4 as described in our previous studies Wang et al., 2019b) , but is able to alter the mRNA and protein levels of APAP-metabolizing CYP enzymes and downstream APAP-induced cytotoxicity in HepaRG cells. These results suggest several critical features of the lncRNAs in the regulation of CYP expression and functions. Firstly, these lncRNAs work as downstream factors to regulate the CYPs together with the transcription factors of HNF1α and HNF4α. Indeed, several studies have suggested that the RNA levels of lncRNAs HNF1α-AS1 and HNF4α-AS1 are controlled by HNF1α and HNF4α Ding et al., 2018; Wang et al., 2019a) . In addition to directly binding to the CYP genes, the transcription factors HNF1α and HNF4α may also regulate CYP expression indirectly through their neighborhood lncRNAs.
Secondly, the lncRNAs have distinct functions in the regulation of their target genes. As showed here and in our previous studies, knockdown of HNF1α-AS1 and HNF4α-AS1 generated opposing effects on the expression of several CYPs at both the mRNA and protein levels, which correlated well with contrasting effects on APAP-induced cytotoxicity. This phenomenon indicates that the lncRNAs HNF1α-AS1 and HNF4α-AS1 may be involved in a dynamic interrelated regulation of CYPs, where both upregulation and downregulation can occur. Generally, the binding of transcription factors to their target genes promotes gene expression, leading to upregulation of gene expression, which is the case for induction of some CYPs by activation of the pregnane X receptor (PXR) or constitutive androstane receptor (CAR) (Burk et al., 2004) . However, how altered expression of CYPs returns to normal basal levels and whether negative feedback loops contribute to the regulation of CYP genes remain largely unknown. The roles of lncRNAs HNF1α-AS1 and HNF4α-AS1, which have opposing effects on the regulation of CYP expression in controlling CYP functions under different physiological conditions, need to be addressed in future studies. Activation of some nuclear receptors, such as PXR and CAR, has been reported to affect AILI (Zhang et al., 2002; Cheng et al., 2009 ).
Expression of PXR or CAR can also been affected by alterations of lncRNAs HNF1α-AS1
or HNF4α-AS1 . These lncRNAs may regulate expression of CYPs and affect susceptibility to AILI through indirect alterations of PXR or CAR, but this assumption needs to be confirmed in a future study.
LncRNAs need cofactors to perform their functions in gene regulation. Studies have shown that lncRNAs are able to interact with other molecules, such as DNA, RNA, and proteins, to perform functions as signaling, decoys, guides, and scaffolds (Wang and Chang, 2011) . Identifying what molecules are able to interact with lncRNAs is a critical step to understand how lncRNAs perform their regulatory functions. One study has showed that HNF1α-AS1 is able to directly interact with miRNA and regulates proliferation and invasion of non-small cell lung cancer cells . LncRNA HNF1αOS1, a neighborhood antisense lncRNA of mouse Hnf1α gene, has been shown to interact with enhancer of zeste homolog 2 (EZH2) in mouse liver by RNA immunoprecipitation sequencing . EZH2 is a catalytic subunit of the polycomb repressive complex 2, which mediates the formation of tri-methylation at histone H3 lysine 27 (Plath et al., 2003; Cifuentes-Rojas et al., 2014) . This evidence suggests that lncRNAs HNF1α-AS1 and HNF4α-AS1 may regulate CYP expression through multiple mechanisms by interacting with different types of molecules. Identification of molecules, mainly miRNAs or proteins, binding to HNF1α-AS1 and HNF4α-AS1, is one of our current research interests to uncover the molecular mechanisms of HNF1α-AS1-and HNF4α-AS1mediated regulation of CYP expression.
LncRNAs should be considered as novel factors predicting drug metabolism and cytotoxicity. By generating loss-of-function cell models, the current study has suggested that expression of lncRNAs HNF1α-AS1 and HNF4α-AS1 is important for APAP-induced cytotoxicity. Notably, in the correlation study performed by Wang and her colleagues using human liver samples, results do not only show that expression levels of HNF1α-AS1 are positively correlated to several CYPs, but also pointed out that HNF1α-AS1 is expressed at different levels among individuals (Wang et al., 2019a) . Besides the wellknown factors that regulate CYP-mediated drug metabolism, which have been shown to impact clinical outcomes of drug treatment, expression and function of CYP-regulating lncRNAs should be also counted as an additional factor (Pinto and Dolan, 2011; Tang and Chen, 2015) . variations in the expression of these lncRNAs. Multiple studies have suggested that lncRNAs are differentially expressed under disease conditions, including cancer, which also suggest that lncRNAs can be affected and expressed differently for a same individual at different times or conditions (Huarte, 2015) . However, no studies have been performed to determine how SNPs in these genes affect expression or function of HNF1α-AS1 and
HNF4α-AS1 or their downstream-regulated genes. More future studies are urgently needed to address these knowledge gaps in their clinical relevance for drug metabolism and cytotoxicity.
In the current research project, HepaRG was used as an experimental model to study the roles of lncRNA in AILI. The hepatoma derived HepaRG cell line has been widely used as a new in vitro model in the study of liver functions due to its high expression levels of drug metabolizing enzymes and transporters (Aninat et al., 2006; Guillouzo et al., 2007) . However, several limitations still exist in HepaRG cell model. The differentiated
HepaRG cells are composed of both hepatocyte-like cells, which act similar to primary hepatocytes, and cholangiocyte-like cells, which act similar to epithelial cells and do not respond to APAP treatment. When harvesting samples from differentiated HepaRG cells, it is difficult to separate these two types of cells, which will ultimately affect the experimental outcomes. Secondary, several SNPs have been identified in HepaRG cells, including CYP2D6, OATP1B1, and MRP2 genes, which may lead to dysfunctions of these proteins. The human primary hepatocytes, which is regarded as the "gold standard model" for in vitro metabolism and toxicity studies will be used in the future to validate our findings in HepaRG cells.
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In conclusion, the present study demonstrates that lncRNAs HNF1α-AS1 and HNF4α-AS1 are able to alter APAP-induced cytotoxicity in HepaRG cells with opposite effects, primarily by affecting expression of the CYP enzymes (Fig.7) .
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 1 . Knockdown of lncRNAs HNF1α-AS1 and HNF4α-AS1 in HepaRG cells. HepaRG cells during a growth period were stably transfected with a negative control shRNA (shNC), shRNAs targeting HNF1α-AS1 (shHNF1α-AS1), or shRNAs targeting HNF4α-AS1 (shHNF4α-AS1). Relative expression of HNF1α-AS1 and HNF4α-AS1 was measured by RT-PCR. The changes of relative mRNA expression compared to the shNC controls were calculated using the 2 -∆∆t method after normalization with GAPDH. Data are shown as mean ± SD (n = 3) and analyzed by two-tailed unpaired Student's t test.
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